We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
DxS  Expand their Portfolio of Cancer Mutation Products, with the Launch of a B-RAF Mutation Detection Kit
Product News

DxS Expand their Portfolio of Cancer Mutation Products, with the Launch of a B-RAF Mutation Detection Kit

DxS  Expand their Portfolio of Cancer Mutation Products, with the Launch of a B-RAF Mutation Detection Kit
Product News

DxS Expand their Portfolio of Cancer Mutation Products, with the Launch of a B-RAF Mutation Detection Kit


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "DxS Expand their Portfolio of Cancer Mutation Products, with the Launch of a B-RAF Mutation Detection Kit "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

DxS has announced the addition of a B-RAF Mutation Detection Kit to their range of oncogene mutation products.

DxS is a molecular diagnostic company specialising in products to detect mutations in tumours. Understanding cancer mutation status can help select the optimal drug therapy for a patient.
 
The DxS B-RAF assay detects V600E, the most common mutation in the B-RAF oncogene, which occurs in many types of cancer including melanoma, colorectal and lung. 

Tumours with the V600E mutation are exquisitely sensitive to drugs that inhibit the MEK pathway; therefore this assay is likely to be useful to investigate which patients will respond to these drugs. Companies with MEK inhibitor drugs in development include Pfizer, AstraZeneca and Roche.  
 
The kit is highly selective and robust, detecting the mutation in a background of wild type genomic DNA in a real time PCR Assay based on DxS ScorpionsÒ technology.

The assay can detect less than 1% of mutant in a background of wild type genomic DNA and has a limit of detection of 5 copies or below. The un-paralleled selectivity of the technology means that the kit detects mutations frequently missed by sequencing methods.
 
Commenting on the B-RAF test, Dr Stephen Little (CEO, DxS Ltd) says, “Patient mutation status is becoming a vital predictor of response to some targeted cancer therapeutics.

The DxS Scorpions test format is rapidly gaining acceptance as both the best and easiest method of mutation testing and this latest addition to our product range will help in the development of personalised medicine for cancer.”

Advertisement